Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Devonian Health Group ( (TSE:GSD) ) has provided an announcement.
Devonian Health Group announced the reinstatement of its common shares on the TSX Venture Exchange following the resolution of a cease trade order due to delayed financial filings. The company has reaffirmed its commitment to compliance and governance, which may positively impact its market position and reassure stakeholders.
More about Devonian Health Group
Devonian Health Group is a clinical stage pharmaceutical company based in Québec, Canada, specializing in the development of drugs for autoimmune inflammatory conditions and cosmeceutical products. The company focuses on innovative therapeutic approaches to address unmet medical needs, particularly in diseases like ulcerative colitis and atopic dermatitis. Devonian also operates a commercialization subsidiary, Altius Healthcare Inc., which sells prescription pharmaceutical products in Canada.
YTD Price Performance: 12.50%
Average Trading Volume: 23,247
Technical Sentiment Signal: Buy
Current Market Cap: C$26.68M
For an in-depth examination of GSD stock, go to TipRanks’ Stock Analysis page.